Stock

Head of Sanofi France: future COVID-19 vaccine underneath 10 euros

© Reuters. FILE PHOTO: The Sanofi logo can be seen at the company's headquarters in Paris, France

PARIS (Reuters) – Olivier Bogillot, head of Sanofi (PA 🙂 in France, said on Saturday that the price of the future COVID-19 vaccine is expected to be less than 10 euros per shot.

"The price is not fully fixed … We estimate the production costs for the coming months … We will be below 10 euros," Bogillot told France Inter Radio.

Drug manufacturers and government agencies around the world are working hard to fight the pandemic and develop vaccines and treatments for COVID-19.

When asked about rival AstraZeneca (L :), which is expected to cost its shot around 2.50 euros in Europe, Bogillot said:

"The price gap for us can be using all of our in-house resources, our own researchers and our own research centers. AstraZeneca is outsourcing some of its production."

Earlier this week, UK-based Sanofi and GlaxoSmithKline (L 🙂 announced that they had started a clinical trial of their protein-based COVID-19 vaccine candidate and that they wanted to reach the final stage of testing by December.

If the results are conclusive, Sanofi and GSK hope the vaccine will be approved in the first half of next year.

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by exchanges, but by market makers. As a result, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading loss you may incur as a result of using this information.

Fusion Media or any person involved with Fusion Media assumes no liability for any loss or damage caused by reliance on information such as data, offers, charts and buy / sell signals contained on this website. Please be fully informed about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.

Related Articles